Premium
P1–313: Reproducibility of intracranial and hippocampal volume quantification at 1.5T and 3T MRI: Application to ADNI I
Author(s) -
Roche Florent,
Singh Baljeet,
Schaerer Joël,
Belaroussi Boubakeur,
Gouttard Sylvain,
Istace Audrey,
Yu Hui Jing,
Fletcher Evan,
Bracoud Luc,
Pachai Chahin,
DeCarli Charles
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.539
Subject(s) - reproducibility , medicine , neuroimaging , alzheimer's disease neuroimaging initiative , biomarker , nuclear medicine , mathematics , dementia , statistics , disease , chemistry , biochemistry , psychiatry
in metabolite levels of the phosphomonoesters phosphocholine (PCho) and phosphoethanolamine (PEtn), and of the phosphodiesters glycerophosphocholine (GPCho) and glycerophosphoethanolamine (GPEtn), inorganic phosphate, phosphocreatine and ATP. Results: High quality 31 P-MRSI spectra with well resolved resonance for phospholipids were obtained (see Figure). Relative levels of PCho, PEtn, GPCho and GPEtn to total phosphorus signal and the ratio of phosphomonoesters to phosphodiesters will be presented for medial temporal lobe, medial prefrontal cortex and posterior cingulate cortex. It is anticipated that data will be presented from a total number of approximately 20 patients. Conclusions: This clinical study will be the first to provide information on brain phospholipid metabolism in multiple brain regions in patients with Alzheimer’s disease. Souvenaid is a registered trademark of N.V. Nutricia.